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1. Introduction 
The lysosome, initially discovered by Christian de Duve in 1955, is an intracellular organelle 
responsible of the ordered degradation of proteins, glycoproteins, proteoglycans, lipids, and 
other macromolecules originated from autophagy, endocytosis and phagocytosis. It is 
characterize by a limiting external membrane containing intraluminal vesicles. These 
organelles are estimated to contain 50-60 soluble acidic hydrolases (Journet et al., 2002), 55 
membrane-associated proteins and 215 integral membrane proteins (Bagshaw et al., 2005). 
The macromolecules are scomposed by acid hydrolases in small molecules that are 
transported back in the cytosol by specific transporter proteins and then catabolized or re-
used by anabolic processes. Lysosomal hydrolases are synthetized as N-glycosylated 
precursors in the endoplasmatic reticulum and are transported to the lysosomes via a 
vectorial transport dependent on mannose 6-phosphate. Lysosomes are involved in many 
cellular processes like cholesterol homeostasis, autophagy, membrane repair, pathogen 
defense, cell signaling, apoptosys and bone/tissue remodelling; it is a foundamental 
organelle for cell life and not only the wastebasket of the cell. Microscopic identification of 
lysosomes is hard due to heterogeneity of organelles morphology dependent on their 
function as digestive organelles. The size and quantity of lysosomes varies in different cell 
types and can increase when the lysosomes accumulate non-digested material. Functional 
deficit of hydrolases, membrane-associated or integral membrane proteins causes lysosomal 
storage disorders (LSDs), a group of inherited metabolic pathologies characterized by 
intralysosomal deposition of undegraded macromolecules and by multisystemic phenotype 
(Saftig, 2006). The absence or reduced activity of a specific lysosomal hydrolase or other 
lysosomal proteins cause an abnormal function of the entire endosomal/lysosomal system 
(Bellettato & Scarpa, 2010). 
More than 50 lysosomal storage disorders (LSD) are known with a total incidence of 1:7,000- 
1:9,000 (Fletcher, 2006). Two thirds of them involve the central nervous system (Meikle et al., 
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1999). The LSD can be classified in sphingolipidoses, mucopolysaccharidoses, 
mucolipidoses, lipid storage disease, glycogen storage disease type II and lysosomal 
transport defects. Different LSD displayed different symptoms severity and different age 
onset and it depend on the organs affected and the residual enzyme activity. Generally, 
mutation leaving very low residual enzyme activity cause the most severe onset form of the 
pathologies; contrary higher residual enzyme activity delays disease onset (Kolter & 
Sandhoff, 1999). The disease course and severity are different in late-onset forms and can be 
variable even among affected siblings in the same family (Zhao & Grabowski, 2002). LSDs 
are often multisystemic disorders and many of these displayed a severe, progressive and 
untreatable neurological impairment. Almost all LSDs are related to devastating, 
progressive and untreatable effects on central nervous system (CNS). Neuronal loss occurs 
in the advanced stages of the diseases and is due to apoptosis or necrosis. The neurological 
symptoms are mental retardation, progressive neurodegeneration, dementia. Most LSDs 
show CNS involvment althought the undegraded material concentration is lower in the 
brain than in other organs. It seems that neurons are more vulnerable than other cellular 
type probably for a limited cell regeneration potential or for the absence of compensatory 
pathways (Bellettato & Scarpa, 2010). The Neuronal Ceroid Lipofuscinoses (NCLs) are 
lysosomal storage diseases  affecting the CNS, with progressive loss of vision, decreasing 
cognitive and motor skills, epileptic seizures and premature death, with dementia without 
visual loss prominent in the rarer adult forms (Kohan et al., 2011). GM1 type 3 
Gangliosidosis is an autosomal recessive lysosomal storage disorder caused by β-
galactosidase deficiency, patients were recently found to be affected by generalized dystonia 
associated to akinetic-rigid parkinsonism (Roze et al., 2005). The San Filippo Syndrome type 
B is a LSDs due to mutation in the gene encoding -N-acetylglucosaminidase with an 
accumulation of heparan sulfate. Affected children shown mental retardation, dementia, 
behavior problems. The analysis of mutant mice showed cytoplasmic inclusion of P-tau 
aggregates, characteristic of tauopathies, a group of age-related dementia that include 
Alzheimer disease (Ohmi et al., 2009). 
In some adult neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease 
and Huntington’ s disease the clical features are similar to those found in LSDs: 
accumulation of undegraded material, abnormal inflammatory response in the brain and 
changes in neurons morphology and functionality (Bellettato et al., 2010). In Parkinson’s 
disease was found an involvement of cathepsin D, a lysosomal enzyme, in -synuclein 
degradation and formation of carboxy-terminally truncated -synuclein. Recent works 
suggest that impaired cathepsin D activity would result in incresed a-synuclein levels that 
cause its aggregation (Sevlever et al., 2008). In Huntington’s disease N-terminal mutant 
huntingtin fragments form inclusions that lead to cell death. Some protease, like cathepsin 
D, B and L, help to degrade mutant huntingtin but increase N-terminal fragment formation 
and inclusions deposition inducing neuronal disruption (Kim et al., 2006). 
2. Gaucher’s disease: An overview 
Gaucher’s disease (GD) is an inherited autosomal recessive metabolic disorder, resulting 
from a deficiency of the lysosomal enzyme β-glucocerebrosidase (also called acid β-
glucosidase, GCase) (EC 3.2.1.45).  
GD was first described as a systemic disease by Philippe Gaucher in 1882, but only in 1965 
this disorder was related to the deficiency of β-glucocerebrosidase (Patrick, 1965; Brady et al. 
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1965). This enzyme is involved in the catabolic pathway of glycosphingolipids and is 
responsible for the cleavage of the β-glucosidic bond on the glucosylceramide (or 
glucocerebroside) (Fig. 1).  
The human฀β-glucosidase is encoded by a gene (GBA) located on chromosome 1 (1q21) 
(Barneveld et al., 1983) which comprises 11 exons and 10 introns, spanning 7.6 kb of 
sequence. A non processed pseudogene (GBAP), which shares 96% exonic sequence 
homology, is located 16 kb downstream of the functional β-glucocerebrosidase gene 
(Horowitz et al., 1989). 
The lack of GCase activity leads to accumulation of glycolipid substrates, primarily 
glucocerebroside and its nonacylated analog, glucosylsphingosine, in all organs, particularly 
in spleen, liver, lungs and bone marrow (Cox & Shofield, 1997; Beutler & Grabowski, 2001). 
The material stored is the product of the arrested breakdown of gangliosides, 
glycosphingolipids and globosides, which derived from the cellular turnover of membranes.  
 
 
Fig. 1. Involvement β-glucocerebrosidase in the catabolic pathway of glycosphingolipids 
Although in the patients the GCase is inactive in all cells, glucocerebroside accumulation 
occurs principally within the lysosomes of macrophages which adopt a characteristic 
“Gaucher’s cell” morphology. Disease manifestations are related to the migration and 
accumulation of the Gaucher’s cells, which displace healthy cells in the tissues. Furthermore 
the abnormal material stored in the cells of the reticuloendothelial system induces the 
release of inflammatory factors, including chemokines and cytokines, which leads to the 
cascade of pathological changes (Beutler & Grabowski, 2001; Cox, 2001; Aerts & Hollak, 
1997; Moran et al., 2000; Jmoudiak & Futerman, 2005; Nilsson & Svennerhol, 1982; Pelled et 
al., 2005; Futerman & van Meer, 2004) (Table 1).  
Gaucher’s disease may occur at any age in any human population (Beutler & Grabowski, 
2001; Zimran et al., 1992; Cox & Shofield, 1997; Erikson, 1986). Although the birth frequency 
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of Gaucher’s disease is one case per 60,000 live births in the general population (Meikle et 
al., 1999), it is the most frequent genetic disease in the Ashkenazi Jewish people where 
epidemiological data, based on estimated gene frequencies, show a prevalence of one case 
per 850 live births (Beutler et al., 1993). 
GD has a highly variable phenotype, and even though a recent trend is to consider GD as a 
continuum of disease states (Goker-Alpan et al., 2003), three basic clinical forms are 
conventionally distinguished on the basis of the neurological involvement: the non 
neuronopathic form (type 1), the acutely neuronopathic form (type 2) and the subacute 
neurophatic form (type 3). 
 
Products Functions 
Lysozyme Antibacterial  
Angiotensin-converting enzyme Vasopressor  
Lysosomal acid hydrolases Digestion  
Interleukin-1b, TNFa Diverse host defence: fever, weight loss 
Interleukin 6 Acute phase response, B-cell stimulation, bone 
resorption, trophic for mieloma cells 
Interleukin 8 Granulocyte chemoattractant 
Interleukin 10  Inhibits pro-inflammatory cytokines 
Table 1. Macrophage secretory products icreased in Gaucher’s disease  
Type 1 GD (OMIM 230800) is the most frequent form of Gaucher’s disease and account 94% 
of all registered cases according to Gaucher Registry. It is a chronic multisystem storage 
disorder which, by definition, does not involve the central nervous system. Nevertheless 
recent studies have shown a possible correlation between type 1 GD and some neurological 
manifestations (Sindransky, 2004; Cherin, 2006; Biegstraaten et al., 2008). In a number of 
cases these symptoms can be the consequence of secondary complications of the primary 
disease (e.g. compression of bone marrow or root nerve as a result of vertebral crush 
fractures caused by osteonecrosis), whereas in other ones they can be the product of specific 
GBA gene mutations, particularly in patients presenting parkinsonian syndromes (Aharon-
Peretz et al., 2004; Bembi et al., 2003; Clark et al., 2005; Gan-Or et al., 2008; Machaczka et al., 
1999; McKeran et al., 1985; Tayeby et al. 2003; Ziegler et al. 2007).  
The type 1 GD course is slowly progressive. Generally the symptoms develop in adulthood 
even though various clinical manifestation may emerge in childhood. The clinical spectrum 
is vast and includes the complete absence of symptoms as well as the severe organ 
involvement with disability and occasionally fatal outcome. The patients show 
hepatosplenomegaly, with thrombocytopenia, anemia and leucopenia. Although in most 
patients these complications are not life-threatening and may go unrecognized for many 
years (some subjects remain asymptomatic up to the age of 70 or 80 years) (Berrebi et al., 
1984), in other ones  this metabolic defect can cause bruising, bleeding  and high risk of 
infection as consequence of pancytopenia and respiratory insufficiency due to diffuse 
infiltration of Gaucher’s cells into the alveolar spaces, perivascular, peribronchial, and into 
the septal regions (Schneider et al., 1977; Lee, 1982). Asthenia and fatigability are constant 
and seem independent of anemia, but rather to reflect an alteration of basal metabolism and 
cytokine secretion (Allen et al., 1997). Moreover degenerative changes in skeleton are the 
leading cause of bone pain and disability in patients with type 1 disease. The infiltration of 
Gaucher’s cells in the bone marrow causes osteonecrosis, particularly during growth and 
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leads to impaired function of large joints, including hip, knee, and shoulder. Other bone 
symptoms include local swelling (Gaucheromas) and osteolysis as well as generalized 
demineralization and osteoporosis with consequent risk of fractures. Furthermore patients 
may show abnormal diffuse yellow-brawn skin pigmentation and delays of growth, 
menarche and dentition. In rare cases there can be also renal involvement, pulmonary 
hypertension (Theise & Ursell, 1990), and cardiac abnormalities.  
Type 2  (OMIM 230900) is the most severe form of Gaucher’s disease which accounts for 
fewer than 1% cases. It manifests in early childhood; neurological deterioration progresses 
quickly and death generally occurs within the age of two years, in a context of psychomotor 
decline (Brady et al., 1993). The majority of cases of type 2 GD emerges around age of 3 
months. The presenting sign is usually hepatosplenomegaly. By 6 months, neurologic 
complications develop. The first diagnostic simptoms are frequently supranuclear 
horizontal oculomotor paralysis or bilateral fixed strabismus accompanied by trismus, 
retroflection of the head, progressive spasticity, hyperreflexia, positive Babinski signs and 
other phatologic reflexes. Other symptoms can be dysphagia and difficulty in handling 
secretions developed, often followed by aspiration pneumonia. Death occurs by either 
apnea or aspiration pneumonia.  
Gaucher’s disease type 3 (OMIM 231000) is particularly frequent in Norbottnian Swedes 
(Erikson, 1986). It leads to subacute neurological symptoms that are less severe than those of 
type 2 disease. It is characterized by the presence of a later onset and a slow progressive 
neurological syndrome. The clinical manifestations vary. Systemic symptoms precede 
neurologic abnormalities and usually are similar to those seen in type 1 GD. Neurologic 
deterioration includes cerebellar ataxia, spastic paraperesis, psychomotor seizures, 
horizontal supranuclear ophthalmoplegia, myoclonic epilepsy and dementia.  
Over 300 mutations of the β-glucosidase gene have been described (Beutler & Gelbart, 1996; 
Geabowski & Horowitz, 1997, Hruska et al., 2008). The most common are c.1226A>G 
(N370S), c.1448T>C (L444P), IVS2+1G>A and 84insG. The frequency and distribution of 
mutations vary with the population studied; in the Ashkenazi population N370S is found in 
78% of patients whereas in non-Jewish populations the most frequent mutation is L444P 
(36%), followed by N370S (29%) (Beutler, 2006).  
Although molecular analysis of the glucocerebrosidase gene in patients with Gaucher's 
disease has permitted broad correlations between genotype and phenotype, this does not 
consent a confident prediction of clinical phenotype (Cox & Sholfield, 1997; Germain, 2004). 
Many studies have shown the enormous clinical variation between patients who have the 
same genotype including monozygotic twins (Sidransky, 2004; Lachmann et al., 2004). 
Nevertheless the presence of N370S on one or both alleles is associated with type 1 GD and 
it seems to protect against neurological symptoms, except for Parkinson-like syndromes 
(Charrow et al., 2000; Cherin et al., 2006). On the contrary the presence of the L444P/L444P 
mutation is associated with the development of neurological manifestations, above all in 
Gaucher’s disease type 3 (75% of cases) (Charrow et al., 2000). Other mutations, including 
84insG, IVS2+1G>A, c.754T>A (F213I) and c.1297G>T (V394L), are generally responsible for 
the emergence of a neurological form, when associated with mutation L444P either alone or 
integrated in a complex allele.  
3. Gaucher’s and Parkinson’s disease: Theories of a link 
Parkinson’s disease (PD) is the one of the common movement disorders and the second 
most common human neurodegenerative disease. The major diagnostic neuropathological 
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features of the pathologiy are loss of dopaminergic neurons and the appearance of Lewy 
bodies (LB), which are intraneuronal inclusions composed by α-synuclein and abnormal 
ubiquitinated proteins aggregates.  
The first associations of the glucocerebrosidase enzyme with parkinsonism were discovered 
through careful clinical observation of people affecting by GD, who in several cases 
developed Parkinson’s disease. Although in recent years GBA mutations were found to be a 
major risk factor for the development of Parkinson’s disease (Sidransky et al., 2009), it is not 
clear how these are related. However many findings suggest that GBA protein and α-
synuclein are implicated in a common cellular pathway and different hypothesis have been 
created to explain the linkage between them.  
Recent studies have shown as some mutations in the GBA gene can lead to the misfolded 
protein formation (Sawkar et al., 2005), contributing to parkinsonism by leading to 
lysosomal insufficiency, as a result of impairing autophagic pathways necessary to prevent 
the synucleopathies, or by crushing the ubiquitin-proteasome system.  
During the life span of a protein, cellular systems continuously check on the quality of the 
protein and take care of its repair or removal from the cell if there is any abnormality. The 
advancement during the past decades in understanding the quality control system of 
cellular proteins has allowed the identification of unequivocal links between malfunctioning 
of these systems and some severe human pathologies, including major neurodegenerative 
disease as Parkinson’s (PD) and Alzheimer’s (AD).  
Many newly synthesized proteins are incorrectly translated or wrongly folded as a result of 
errors in their sequence due to either genetic mutations or alterations during the synthesis 
process (Wheatley & Inglis, 1980; Vabulas & Hartl, 2005; Shubert et al., 2000; Yewdell, 2005). 
The role of protein catabolism in protecting cells from defective, misfolded proteins is 
essential to avoid the risk of long term accumulation of proteins which frequently develop 
abnormal intermolecular interaction, forming insoluble aggregates toxic for the cells (Squier, 
2001; Kourie & Henry, 2001). So it is evident the involvement of the quality control system in 
maintaining cell homeostasis as well as the association between the alteration of the protein 
turnover and many disease states (Kundu & Thompson, 2008). The autophagy-lysosome 
and the ubiquitin-proteasome pathways are the two main routes of the quality control 
system in eukaryotic.  
Autophagy-lysosomal degradation pathway is a complex system tightly regulated by series 
of signaling events that promote the efficient delivery of macronutrients and organelles to 
lysosomes for degradation by acidic hydrolases (Levine & Klionsky, 2004). It is implicated in 
the catabolism and recycling of long-lived proteins and organelles and it is thought to be 
involved in many physiological processes, including the response to starvation, cell growth 
control, antiaging mechanisms and innate immunity. Some years ago the authophagy-
lysosome pathway was considered as a non selective form of catabolism, while now the 
view is changed and it is thought as a specialized system that distinguishes the substrates 
and chooses the route by which they reach the lysosomes. Three types of autophagy have 
been described: macroautophagy, microautophagy and chaperon mediated autophagy 
(CMA) (Cuervo, 2004). They share a common endpoint, the lysosome, but differ in 
substrates targeted, their regulation and the conditions in which each of them is 
preferentially activated.  
Macroautophagy process is activated to generate essential macromolecules and energy in 
condition of nutritional scarcity (Mizushima, 2005) or as a mechanism to remove the altered 
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intracellular components (Levine & Klionsky, 2004). It can be induced also by hypoxia, 
neurotrophic factor deprivation, excitotoxins and accumulation of protein aggregates 
through PI3K and ERK-mediated pathways (Zhu t al., 2007; Boland & Nixon, 2006). 
Macroautophagy is described as the sequestration of complete regions of the cytosol, 
including not only soluble proteins, but also complete organelles, into a double membrane 
vescicle known as autophagosome, which is considered an immature form of autophagic 
vacuole (AV) (Seglen et al., 1996; Mortimore et al., 1996). The limiting double membrane is 
thought to arise from the endoplasmatic reticulum, although the Golgi complex has also 
been indicated as a source (Levine & Klionsky, 2004; Mijaljica et al., 2006). Because these 
vesicles lack any enzyme, the trapped contents are not degradated until the autophagosome 
founds with a lysosome, forming a single membrane autophagolysosome.  
Macroautophagy is regulated by the action of a family of molecules, known as autophagy-
related proteins (Atg), which participates in each of the different steps of this process 
(Klionsky et al., 2003). A series of conjugation events (protein-to-lipid and protein-to-
protein) and several members of intracellular kinase families are involved (Klionsky, 2005; 
Ohsumi, 2001).  
One hypotheses has been proposed to explain the role of dysregulated autophagy in PD 
pathogenesis, in patients affected to Gaucher’s disease. This theory (“offensive metabolite 
theory”) is based on the ceramide activity in the process of autophagic pathway modulation 
(Scarlatti et al., 2004).  Ceramide is a sphingolipid mediator with an essential role in different 
situations correlated with authophagic system, such as cell growth, cell death, proliferation 
and stress response (Klionsky & Emr, 2000). Studies have shown as ceramide  interferes 
with the inhibitory class I PI3K signaling pathway and induces the expression of a 
autophagy-related gene beclin 1, stimuling the autophagyc process.  
It’s possible that the lack of β-glucocerebrosidase activity and the accumulation of 
glucocerebroside may interfere with the ceramide modulation system, destroing cellular 
pathways necessary for autophagic-lysosomal degradation and leading to the LB formation.  
The other types of described autophagy are microautophagy and CMA. The first one 
consists of direct engulfment of small volumes of cytosol (constituted by soluble proteins 
but also by complete organelles) by lysosomes (Ahlberg et al., 1982) through invaginations 
or tabulations that “pinch off” from the membrane into the lysosomal lumen where they are 
rapidly degraded (Marzella et al., 1981). Microautophagy participates in the continuous 
turnover of long-lived proteins inside many types of cells (Mortimore et al., 1988); in 
addition a number of studies have shown as a particular form of microautophagy can lead 
to preferential degradation of peroxisomes (micropexophagy) (Farre and Subramani, 2004; 
Mukaiyama et al., 2002; Veenhuis et al., 2000).  
Chaperon-mediated autophagy is characterized by selectivity; about 30% of cytosolic 
proteins are degraded by this pathway. Through CMA particular cytosolic proteins are 
recognized by a chaperone in the cytosol, which delivers the proteins directly to the surface 
of the lysosome (Dice, 1990; Majeski & Dice, 2004, Massey et al., 2006). A distinctive feature 
of this pathway is that all substrate proteins contain in their amino acid sequence a motif, 
biochemically related to the pentapeptide KFERQ, required for targeting to the lysosomal 
compartment (Dice, 1990). A heat shock protein, hsc73 (Chiang et al., 1989) , recognizes the 
substrates containing the motif, and brings them to the lysosome membrane, where it binds 
to the receptor protein, lamp2 (lysosome-associated membrane protein type 2a) (Cuervo & 
Dice, 1996). The substrate interacts direcly with lamp2, and once unfolded, it is transported 
in the lysosome lumen (Salvador et al., 2000) where it is degraded.  
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Substrates for CMA consist of a very heterogeneous pool of cytosolic proteins, different for 
structure and function, but having all the same KFERQ motif. CMA acts in the degradation 
of many different substrates (i.e. several glycolitic enzymes, glutathione transferase,  
ribonuclease A) and damaged proteins: its selective role allows removal of the altered 
proteins without affecting neighbouring healty ones (Kiffin et al., 2004; Cuervo et al., 1999). 
Many studies have shown as this autophagic pathway is activated when stress condition  
occurs in the cells, such as prolonged nutrient deprivation or exposure to toxic compounds 
(Cuervo & Dice, 1998).  
Independently of the autophagic pathway, all substrates are brought to the lysosome lumen 
where several different lysosomal hydrolases rapidly degrade them. These enzymes are 
synthesized in the endoplasmatic reticulum, sorted to the trans-Golgi network by mannose-
6-phosphate receptors, transported through the endosome to arrive to their lysosomal 
destination, where they are activated upon the exposure to the acid environment (Jadot et 
al., 1997). The proteolytic capacity of lysosomes comprises a mixture of endo- and exo-
peptidases, called cathepsins, which act in concert to degrade proteins to a mixture of amino 
acids and dipeptides. Expression, activation and inhibition of these cathepsins are 
differentially regulated, and individual cathepsins often have non-redundant functions in 
normal and disease states (Kroemer & Jaattela, 2005). In addition to peptidases activity, 
intralysosomal conditions and other lysosomal components (i.e. glycosidase, lipases, 
phospholipases, solphatases, nucleases and phosphatases) are designed to favor the 
complete degradation of the internalized products.   
One route of degradation of the α-synuclein is via CMA pathway (Cuervo et al., 2004). 
Studies have revealed as impaired lysosomal function seems to be involved in familial forms 
of PD, as consequence of reduced α-synuclein degradation. So one theory is that 
disturbances in the lysosome (i.e. the alteration in the GCase function) contribute to reduce 
α-synuclein degradation and consequently promote its aggregation. This may be possible 
since ceramide can activate cathepsin D (aspartate protease), which in turn is responsible for 
the proteolytic activation of other lysosomal proteins (Heinrich et al., 1999). So the reduced 
activity of one protease can spark off the decremented action of other acid hydrolases 
causing an α-synuclein accumulation and contributing in LB formation.   
The other฀α-synuclein degradation pathway is the ubiquitin-proteasome system (UPS). It 
serves as the primary route for the degradation of thousands of short-lived proteins and 
provides the specificity and temporal control needed for tuning the stady-state levels of many 
regulatory proteins (Ciechanover et al., 2000). UPS-mediated catabolism is also essential to 
preserve amino acid pools in acute starvation and contributes significantly to the degradation 
of defective proteins (Ciechanover & Brudin, 2003; Whealtley & Inglis, 1980; Vabulas & Hartl, 
2005). UPS contributes also to diverse cellular processes, such as protein quality control, cell-
cycle progression, signal transduction, and development (Kerscher et al., 2006).  
Substrates of the ubiquitin/proteasome system (UPS) get post-translationally modified by 
covalent attachment of multiple ubiquitin molecules at internal lysine residues. This 
polyubiquitylation of substrate proteins involves three enzymes: ubiquitin-activating 
enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin protein ligases (E3). E1 
hydrolyses ATP and forms a thioester-linked conjugate between itself and ubiquitin; E2 
receives ubiquitin from E1 and forms a similar thioester intermediate with ubiquitin; and E3 
binds both E2 and the substrate, and transfers the ubiquitin to the substrate. A chain made 
of four to six ubiquitin moieties targets the conjugated substrate for degradation by the 26S 
proteasome (Richly et al., 2005; Zhang et al., 2009).  
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The UPS can only degrade proteins when they are in a soluble state or as a part of reversible 
protein complexes that can be disassembled into single protein units (Finkbeiner et al., 2006; 
Kopito, 2000). So any type of irreversible oligomeric structures, preaggregates, and protein 
aggregates cannot be handled by UPS, instead they can be degraded by the autophagic-
lysosomal pathway.  
A different theory (“misfolded protein theory”) to explain the linkage between Gaucher’s and 
Parkinson’s disease, is that mutant misfolded glucocerebrosidase might overwhelm the UPS, 
causing a delay in the degradation of accumulated proteins, including α-synuclein (Dawson, 
2006). Ron et al. have shown that misfolded GCase endures endoplasmatic reticulum 
associated degradation (ERAD) (Ron and Horowitz, 2005). In this process, mutant proteins are 
identified as misfolded by the ER quality control system and retrotraslocated from ER to 
cytosol, ubiquitinated and eliminated by the ubiquitin-proteasome system.  The same authors 
proposed that mutated GBA protein (but not WT GBA) undergoes parkin (E3-ligase)-mediated 
ubiquitination, creating an imbalance in protein degradation resulting in secondary toxicity. It 
is likely that, since GCase is not a natural substrate of parkin, the enduringly ER retention and 
proteasomal degradation of mutant β-glucosidase, mediated by parkin, affect its activity 
toward its natural substrates. Accumulation during the years of these proteins can lead to the 
death of cells in substantia nigra and eventually, to the development of PD.  
The theories described above, cannot explain completely the correlation between the 
diseases.  In the “offensive metabolite theory” the reducing of the released ceramide inhibits 
the autophagic-lysosomal functions. This can explain the development of LB and 
parkinsonism in Gaucher patients, but not in GBA mutations carriers.  
Moreover in Gaucher patients where mutations in GBA result in no protein product (i.e. 
c.84dupG and IVS2+1G>A) the risk to develop PD is high. So the “misfolded protein 
theory” also cannot clear fully  the question, even if it is probably that very truncated forms 
of the mutant protein still might induce endoplasmic reticulum stress and guide to crashing 
of UPS. 
4. Genetic studies and neuropathological data 
The first indication of a relationship between parkinsonism and GD was due to sporadic 
case reports in the literarture (Neudorfer et al., 1996; Machaczka et al., 1999; Tayebi et al., 
2001). In these papers it was highlighted how in some GD patients the enzyme deficiency 
itself could predisposed to the susceptibility to parkinsonisms. 
These observations of occurrence of Parkinson’s disease in some patients with non-
neuropathic type 1 Gaucher disease and in their first degree relatives has led to the 
identification of GBA1 heterozigous mutations as a genetic risk factor for  idiopathic 
Parkinson’s disease. 
In these subjects the mean age at onset of parkinsonian symptoms is lower than in patients 
without GD1, becoming evident at an average age of 48 years compared with 71 years in the 
general population (Elbaz et al., 2003).  
These early observations led to several studies which revealed that patients with idiopathic 
PD had a higher probability of harboring GBA1 mutations compared to the general 
population. 
The first large study was conducted by Lwin et al. (2004), using sequence analyses on brain 




Etiology and Pathophysiology of Parkinson's Disease 
 
468 
Subsequently Aharon-Peretz et al. (2004), explored the association between six GBA 
mutations (N370S, L444P, c.84dupG, IVS+1A>G, R496H, V394L) and PD in Ashkenazi Jews 
population. From the screening of 99 patients and 1,543 healty people they identified these 
mutations in 31.3% of patients with PD versus 6.2% of healty controls.  
Many studies have been conducted in the years, some of these have been screened PD 
patients for common GBA mutations (Clarck et al., 2005; Sato et al., 2005; Tan et al., 2007; 
Wu et al., 2007; De Marco et al., 2008; Spitz et al., 2008; Mata et al., 2008; Gan-Or et al., 2008), 
others have been sequenced the entire GBA gene (Eblan et al., 2006; Ziegler et al., 2007; 
Clark et al., 2007; Bras  & Singleton, 2009; Kalinderi et al., 2009; Neumann et al., 2009). 
All of these studies evidenced a higher frequency of GBA mutations among PD patients than 
in matched controls, but the frequency of GBA mutations varies in relation with the study’s 
design (popolation, number and type of mutations screened or whole GBA scanning).  
Toft et al. (2006) searched the association between two mutations (N370S and L444P) and PD 
in Norwegian population. From the analyses of 311 patients and 474 controls they found 
these mutations in 2.3% of subjects with PD versus 1.7% of controls. 
The frequency of GBA mutations ranges between 10.7% and 31.3% in PD patients from 
Ashkenazi Jewish and between 2.3% and 9.4% in patients from other populations. 
Most of these studies were conducted on sporadic PD patients, recently Nichols et al. (2009) 
and Mitsui et al. (2009) specifically investigated familial PD. They demonstrated an 
association between GBA variants and familial PD cases as well as sporadic disease. 
Most of these studies have independently reached similar results demonstrating that GBA 
mutations are found in patients with PD at a higher frequency than expected.  
A large meta-analysis was conducted by Sidransky et al. (2009) pooling genotypic data from 16 
different centers across the world. A total of 5,691 genotyped patients with Parkinson disease 
and 4,898 controls were evaluated; full sequencing was performed on 1859 patient and 1674 
control samples. Overall, the odds ratio for carryng a GBA mutation in subjects with PD was 
5.43 (95% CI 3.89-7.57), selecting mutations in GBA gene as a common risk factor for PD. 
Investigators extended their studies to analyses whether GBA mutations are related with 
other Lewy bodies disorders. Goker-Alpan et al. (2006), analyzing the coding region of GBA 
gene in 75 brain’s sample of autopsy cases with pathologically confirmed Lewy body 
disorders, found GBA mutations in 23% of LBD patients, 4% of PD patients and none within 
Multiple System Atrophy patients (MSA). 
Afterward Mata et al. (2008), Farrer et al. (2009) and Clark et al. (2009) showed a correlation 
between GBA mutations and LBD, while was found no significant difference in GBA 
mutations incidence between MSA patients and controls (Segarane et al., 2009). 
Considering the spectrum of PD clinical manifestations in GD1 patients, a wide range of 
symptoms have been described, varying from the more aggressive, early-onset disease, with 
poor response to L-dopa therapy, to the more typical PD disease (presenting with 
asymmetric onset of resting tremor, bradykinesia, rigidity, gait and balance disturbance, 
weakness, pain, cognitive decline, and depression), responsive to L-dopa (Neudorfer et al., 
1996; Tayebi et al, 2003; Bembi et al., 2003; Tayebi et al, 2001; Halperin et al. 2006; Gan-Or  et 
al., 2008; Bultron et al., 2010; Chérin et al., 2010;). The emerging evidence of the association 
between GBA mutations and a variety of synucleinopathyes may account for the wide 
phenotype variability (Hruska at al., 2006; Velayati et al, 2010). Even if different studies 
described early-onset (< 50 years) as an element that characterizes this association, this 
observation might be influenced by the small number of patients involved in each study.  
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Trying to find an answer to this issue, Gan-Or et al. (2008) performed a study analysing a 
large cohort of 420 unrelated Jewish Ashkenazi PD patients, which evidenced a strong 
correlation between GD1 and early-onset of PD symptoms (average age at onset of 51.2 
years, versus 60.7 years of the noncarriers PD population), while GBA carriers showed an 
average age of 57.2 years at PD onset. 
They also analysed the different effects of mutation severity, observing a higher risk for PD 
in patients carrying severe GBA mutations as well as a decreased age of symptoms onset. 
Finally, when they analysed clinical PD manifestations among GBA carriers and non-
carriers, they observed a reduced presence of rigidity (16.90% vs 28.57%) and an increase of 
weakness (16.90% vs 7.14%) in GBA carriers. 
Another recent large observational study of 444 consecutive GD1 patients (Bultron et al., 
2010), aiming to analyse the risk of PD occurrence, showed 11 patients (2.47%) who 
developed the disease at a mean age of 55.0 ± 8.8 years (range 40-65 years). Analysing GD 
overall severe score index (SSI) and bone disease score (Hermann score) in the overall 
population, they found both of them significantly higher in PD patients (SSI: 10.8±0.8 vs 
6.9±3.7, p=0.02; Herman score: 4.6±0.5 vs 2.5±1.5, p=0.002). 
Moreover, these authors estimated age and gender-adjusted risk to develop PD in three 
different groups of GD1 patients, finding that the range of risk was increased 11.0 to 31.3 
fold in male patients and 5.7 to 13.8 fold in female patients, with an overall relative risk to 
develop PD in GD1 patients of 21.4 (95% CI, 10.7-38.3). 
As regard the clinical response to ERT in GD1 patients with PD, all published experiences 
demonstrated its effectiveness on hematological and systemic involvement, while they were 
ineffective in correcting PD symptoms (Neudorfer et al., 1996; Tayebi et al, 2003; Bembi et 
al., 2003; Tayebi et al, 2001; Itokawa et al., 2006; Bultron et al., 2010). The new era of 
substrate reducing and chaperone therapies with small molecules that are able to cross the 
blood-brain barrier may open new perspectives in the treatment of central nervous system 
involvement in GD, including PD symptoms. A recent report of Hughes et al. (2007) that 
showed an improvement in the clinical conditions of a PD patient during SRT with 
Miglustat, introduces a new possible therapeutic approach.  
5. Expression of GBA and other lysosomal enzyme in animal models of 
Parkinson’s disease 
The majority of sporadic PD cases result from interaction between genes and environment 
but the age remains the greatest risk factor. The first evidence of a genetic involvement in 
PD manifestations was the identification of three missense mutations on the α-synuclein 
gene, SNCA. These mutations (A30P, E46K, A53T) segregate with the disease in unrelated 
families and caused PD with high penetrance (Polymeropoulos et al., 1997; Kruger et al., 
1998; Zarranz et al., 2004). Afterward duplication and triplication of the SNCA gene has 
been shown to cause PD, suggesting that high level expression of α-synuclein may also be 
pathogenic (Singleton et al., 2003; Ibanez et al., 2004). The degree of overexpression was 
found to correlate with the degree of severity of the pathology. The effects of point mutation 
and duplication-triplication of SNCA gene have been investigated using transgenic 
technology and viral infection and different mouse models were created. All PD animal 
models are based on the concept that parkinsonian signs are linked to dopaminergic nigral 
cell loss and even if they show many of the symptoms of the disease they don’t display all 
the complexity of the neurological pathology. A lot of mouse line expressing wild-type or 
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mutant α-synuclein (Masliah et al., 2000; Lee et al., 2002; Richfield et al., 2002) was found to 
lead to the develp of granular deposits, but none of these results in the involvment of 
dopaminergic nerve cellsof the substantia nigra. Previous data demonstrated that truncated 
α-synuclein (1-120) was aboundantly presents in Lewy bodies extracts (Tofaris et al., 2003). 
There are two different animal models of Parkinson’s disease: the first one is a mouse model 
that express a truncated human α-synuclein (1-120) under the rat tyrosine hydroxylase 
promoter on a mouse α-synuclein null background (Tofaris et al., 2006). In this mouse 
model (TG Syn 120) were found pathological inclusions in substantia nigra and olfactory 
bulb, a reduction in dopamine levels in the striatum and in spontaneous locomotion and a 
better response to amphetamine. C-terminally truncated α-synuclein aggregates more 
quickly than full-lenght protein and has been found in Lewy bodies in human patients. The 
second one is a rat model (6OH-DA) with the lesion of the ascending nigrostriatal dopamine 
pathway due to 6-hydroxydopamine injection in the unilateral substantia nigra (Rozas et al., 
1997; Picconi et al., 2003). These rats displayed some feautures of parkinsonian pathology. 
This rat model has been initially used to understand the behavioral functions of the basal 
ganglia, and to evaluate the brain’s ability to compensate for specific neurochemical 
depletions. Now this model is use has strument to understand the mechanisms of PD 
pathology and as an experimental basis to develop new antiparkinsonian drugs and 
treatment strategies, or surgical approaches (Rozas et al., 1997). To deepen the involvement 
of lysosomal enzyme in Parkinson’s disease,  a comparative analysis of the activity of β-
glucocerebrosidase (EC 3.2.1.45), α-mannosidase (EC 3.2.1.24), β-mannosidase (EC 3.2.1.25), 
β-hexosaminidase (EC 3.2.1.52) and β-galactosidase (EC 3.2.1.23) have been performed in 
different brain sections of the two animal’s model.  
In particular lysosomal enzymatic activities were determined in cerebellum, cortex and 
brain-stem. The obtained results show a different expression in these sections of central 
nervous system of TG Syn 120 mouse model compared to control mice, with a decreased 
activity of all the enzymes in brain-stem, and an increased activity in the cerebellum. In the 















Wistar 20.37±4.33 0.45±0.17 0.32±0.08 3.70±1.22 0.15±0.1 
6OH-DA 17.61±5.75 0.31±0.1 0.23±0.1 2.82±0.91 0.15±0.08 
cerebellum 
Wistar 16.43±3.42 0.51±0.23 0.36±0.13 3.88±0.83 0.1±0.04 
6OH-DA 11.27*±2.5 0.25*±0.05 0.22*±0.05 2.64*±0.81 0.08±0.02 
cortico-
striatal 
Wistar 18.81±3.64 0.3±0.05 0.39±0.29 1.30±0.83 0.1±0.04 
6OH-DA 12.85*±0.92 0.167*±0.03 0.11*±0.03 0.48±0.38 0.05*±0.022 
Table 2. Lysosomal enzyme specific activities (µmol min-1/mg total protein x 1000) in, 
cerebellum, cortico-striatal and brain-stem of control and 6OH-DA rats. Mean ± SD are 
given. *p<0.05 versus control. 
A more pronunced differences in lysosomal enzyme expressions were observed in 6OH-DA 
rats (table 2). A clear reduction of enzyme activities were found in brain-stem, cerebellum 
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and cortico-striatal.  The chemical model show a profound involvement of the brain’s areas 
and this is, probably, a consequence of the 6-hydroxydopamine treatment, infact the 
neurotoxins destroied selectively and rapidly catecholaminergic neurons whereas the PD 
pathogenensis in human and in the mouse model follows a progressive course over decades. 
The results obtained in this rat model might explain the reduction on alpha-mannosidase, 
beta-glucosidase, and beta-mannosidse activities observed in the CSF od PD patients 
(Balducci et al., 2007). 
6. CSF lysosomal enzyme activities as possible marker of synucleinopathies 
Recently it became evident that accumulation of unwanted and misfolded protein play a 
central role in the PD pathogenesis. An involvement of the lysosomal system has been 
postulated. Lysosomal activity decreased over the lifespan and a lysosomal malfunction has 
been linked with cronic neurodegenerative disorders (Terman, 2006; Pan et al., 2008). This 
assumption has been confirmed by the selective inhibition of lysosomal enzyme in different 
cellular models that leads to protein aggregation, synaptic loss and neuronal death (Felbor 
et al., 2002; Bendiske & Bahr, 2003). Furthermore, in experimental system, has been noted 
that α-synuclein aggregation leads to inhibition of lysosomal functions, triggering  a vicious 
cycle (Bennett et al., 2005; Cuervo et al., 2004). On the basis of these evidences was 
performed a comparative analysis of the activity of฀β−glucocerebrosidase (EC 3.2.1.45), α-
mannosidase (EC 3.2.1.24), β-mannosidase (EC 3.2.1.25), β-hexosaminidase (EC 3.2.1.52) and 
β-galactosidase (EC 3.2.1.23) in cerebrospinal fluid (CSF) of Parkinson’s disease (PD) 
subjects and age matched controls first (Balducci et al., 2007), and then in Dementia with 
Lewy bodies (DLB), Alzheimer’s disease (AD) and Frontotemporal Dementia (FTD) patients 
as well as in age matched controls (Parnetti et al., 2009). The framekork is different in the 
different neurodegenerative diseases, in PD patients a reduced activity of  β-
glucocerebrosidase, β-mannosidase and α-mannosidase  was found, whereas β-
galactosidase and β-hexosaminidase remain unchanged. In DLB patients, all the enzymes 
tested showed a decrease activity with β−glucocerebrosidase with the lower value. In FTD 
patients, only α-mannosidase activity was lower than controls, while the other enzymes 
showed unchanged acticities. α-mannosidase and β-hexosaminidase are the only two 
enzyme that showed reduced activity in AD patients. 
The data suggest a significant involvement of the ensosomal-lysosomal system in the 
neurodegenerative diseases examined. Moreover, the different pattern of lysosomal activity 
can reflect the diverse implication of the lysosomal apparatous in the distinct 
neurodegenerative pathologies. It has also been hypotized that ameliorate the activity of the 
lysosomal system can be a possible therapeutic strategy for these disorders characterized by 
misfolding and aggregation of wild-type or mutant protein in the cytoplas of neuronal cells 
(Lee et al., 2004). 
7. Conclusion  
Clinical and genetic studies suggest that mutations in the glucocerebrosidase gene are an 
important risk factor for the development of parkinsonism and related didorders. While 
Gaucher disease is an autosomal inherited disorder, patients with parkinson’s disease can be 
Gaucher heterozygotes or homozygotes. The involvment of the lysosomal system in 
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parkinson’s disease has also been further demonstated by the different expression of  
lysosomal enzymes, such as  β-glucosidase, α-mannosidase, β-mannosidase, and β-
galactosidase  in CSF and in the brain of animal models. The elucidation of the molecular 
basis of this association may contribute to understand the development of parkinsonism. 
Anyway it is still unclear which is the common cellular pathway that links Gaucher and 
Parkinson diseases. 
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